431 Galectin-3 as a Biomarker and Potential Therapeutic Target in Biliary Atresia
431 Galectin-3 as a Biomarker and Potential Therapeutic Target in Biliary Atresia
About this item
Full title
Author / Creator
Publisher
Cambridge: Cambridge University Press
Journal title
Language
English
Formats
Publication information
Publisher
Cambridge: Cambridge University Press
Subjects
More information
Scope and Contents
Contents
OBJECTIVES/GOALS: Biliary atresia (BA) is a progressive congenital disease that is characterized by periductular inflammation and fibrosis that leads to bile duct destruction and cholestasis in neonates. Galectin-3 (Gal3) plays a key role in inflammation and fibrosis. The aim of this study was to evaluate plasma Gal3 levels in early and late BA. ME...
Alternative Titles
Full title
431 Galectin-3 as a Biomarker and Potential Therapeutic Target in Biliary Atresia
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_69cc27cafea6499bb7a32de03aa17b7c
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_69cc27cafea6499bb7a32de03aa17b7c
Other Identifiers
ISSN
2059-8661
E-ISSN
2059-8661
DOI
10.1017/cts.2022.250
